| Literature DB >> 35720184 |
Anshu Sharma1, Ruchi Sharma2, Munisha Sharma3, Manoj Kumar4, Mrunal Deepak Barbhai4, José M Lorenzo5,6, Somesh Sharma2, Mahesh Kumar Samota7, Maria Atanassova8, Gianluca Caruso9, Mo Naushad2, Deepak Chandran10, Pramod Prakash11, Muzaffar Hasan12, Nadeem Rais13, Abhijit Dey14, Dipendra Kumar Mahato15, Sangram Dhumal16, Surinder Singh17, Marisennayya Senapathy18, Sureshkumar Rajalingam19, Marthandan Visvanathan20, Lejaniya Abdul Kalam Saleena21, Mohamed Mekhemar22.
Abstract
The prevalence of viral infections, cancer, and diabetes is increasing at an alarming rate around the world, and these diseases are now considered to be the most serious risks to human well-being in the modern period. There is a widespread practice in Asian countries of using papaya leaves (C. papaya L.) as herbal medicine, either alone or in combination with prescribed medications, to treat a variety of ailments. The importance of conducting the necessary descriptive studies in order to determine the safety of papaya leaf consumption is also emphasized in the context of their application in the healthcare sector. Electronic databases such as Google Scholar, Scopus, and PubMed were used to gather information on papaya leaves, their therapeutic potential, and clinical evidence-based studies. The literature was gathered from publications on papaya leaves, their therapeutic potential, and clinical evidence-based studies. The antidengue, anticancer, antidiabetic, neuroprotective, and anti-inflammatory effects of papaya leaves discussed in this article are supported by evidence from preclinical, in vivo, in vitro, and clinical trial studies, as well as from other sources. Leaves have been investigated for their mechanism of action as well as their potential to be used in the development of novel herbal products for the health business. According to the reports gathered, only a small number of research demonstrated that leaf extract at high concentrations was hazardous to certain organs. The collective literature reviewed in this review provides insights into the use of papaya leaves as a cure for epidemic diseases, highlighting the phytochemical composition and pharmacological attributes of papaya leaves, as well as the results of various preclinical and clinical studies that have been conducted so far on the subject. The review clearly demonstrates the successful medical evidence for the use of papaya leaf extracts in the healthcare system as a supplemental herbal medication in a variety of clinical settings.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35720184 PMCID: PMC9203216 DOI: 10.1155/2022/2451733
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 7.310
Figure 1Chemical constituents and structure of some important compounds of C. papaya leaves. (a) Constituents of C. papaya leaves along with functional uses; (b) chemical structures of important bioactive compounds present in C. papaya leaves.
Antioxidant activities of Carica papaya L. leaf extract.
| Type of extract | Method used | Responsible phytochemicals | References |
|---|---|---|---|
| Methanol | Peroxynitrite scavenging assay | Kaempferol 3-(2G-rhamnosylrutinoside) | [ |
| Ethanol, methanol, and water | DPPH, FRAP | Flavanoids | [ |
| Methanol | DPPH | Carpaine, kaempferol 3-(2G-glucosylrutinoside), kaempferol 3-(2″-rhamnosylgalactoside), 7-rhamnoside, kaempferol 3-rhamnosyl-(1->2)-galactoside-7-rhamnoside, luteolin 7-galactosyl-(1->6)-galactoside, orientin 7-O-rhamnoside, 11-hydroperoxy-12,13-epoxy-9-octadecenoic acid, palmitic amide, and 2-hexaprenyl-6-methoxyphenol | [ |
| Methanol | DPPH | — | [ |
| n-Hexane, dichloromethane, ethyl acetate, ethanol, methanol, n-butanol, and water | DPPH | Phenolics and flavonoids | [ |
| Aqueous | DPPH, ABTS | Polyphenols | [ |
| Methanol | Phosphomolybdenum method | Flavonoids | [ |
| Aqueous | DPPH, ABTS+ assay | Proteins and phenolic groups | [ |
Figure 2Antiviral (antidengue) and antithrombocytopenic effect of papaya leaves.
Medicinal potential of Carica papaya L. leaf extract against virus-induced thrombocytopenia.
| Treatment | Results | References |
|---|---|---|
| Mature | (i) Increase in platelet count without toxicity in rats | [ |
| Fresh | (i) Increment in the platelet and the RBC count. | [ |
|
| (i) Increase in no. of in thrombocytes (28 · 103/mL to 138 · 103/mL) and white blood cells BC (3000/mL · 7800/mL) in a dengue adult patient | [ |
| Administration of 500 mg papaya leaf extract capsules on daily basis along with supportive medical treatment for five days to patients | (i) Increment in platelet count | [ |
| Carpaine extracted from | (i) Isolated carpaine from | [ |
| Aqueous extract of | (i) Increase in number of a platelet count of dengue-infected children of age 10 and 14 | [ |
| Aqueous extract of | (i) Significant increase in the platelet an white blood cell count after 2 days of treatment | [ |
| Standardized | (ii) Oral administration showed a significant increase in thrombocytes (1014.83 cells/mm3), DTH response (0.16), and phagocytic index (63.15% increase) | [ |
|
| (i) After 5 days, the mean increase in platelet counts from 101.93 × 103/ | [ |
| Administration of papaya leaf extract (1.1 g) to total five hundred patients suffering from thrombocytopenia three times daily for five days | (i) A significant increase in counts of platelets were noticed in the study group. | [ |
| Treatment of infected mice with 1000 mg/kg bw of FCPLJ (freeze-dried | Increase in the number of total white blood cell and neutrophil counts by 1.44-fold. | [ |
Medicinal potential of Carica papaya L. leaf extract against virus-induced thrombocytopenia.
| Treatment | Effect on cancerous cells | References |
|---|---|---|
| Aqueous isolate of | (i) Exhibited an effective anticancer property on cancer cell lines (stomach cancer cell line (AGS), pancreatic cancer cell line (Capan-1), colon cancer cell line (DLD-1), ovarian cancer cell line (Dov-13), lymphoma cell line (karpas), breast cancer cell line (MCF-7) | [ |
| Aqueous extract of | (i) Inhibition of proliferative responses of haematopoietic cell lines and solid tumour cell lines | [ |
| Brewed leaf juice (20 mg/mL) | (i) Effective antiproliferative activity against cancerous cells of the prostate | [ |
| Aqueous | (i) Antiproliferative and apoptotic induced effect of papaya leaf inhibits the proliferation of human breast cancer cell | [ |
| Papaya leaf juice and its various extracts (0.25–0.1 mg/mL) | (i) Effective antiproliferative activity against cancerous cells of the prostate | [ |
|
| (i) Decrease the cancer cell proliferation | [ |
| Silver nanoparticles (AgNPs) with papaya leaf extract (0.5, 1, 2.5, and 5 | Reduction in cell proliferation and subsequent apoptosis of human prostate carcinoma DU145 cells. | [ |
Figure 3Anticancer activities of papaya leaf extract.
Immunomodulatory potential of papaya leaf extract.
| Treatment | Results | References |
|---|---|---|
| Oral administration of SCPLE (150 mg/kg) in thrombocytopenic rats | Significant ( | [ |
| Administration of | Proinflammatory cytokines (IL-10, IL-12, IL-1 | [ |
| Aqueous-extracted CP leaf fraction on the growth of various tumor cell lines | Production of IL-2 and IL-4 was reduced. | [ |
In vivo studies on the medicinal potential of Carica papaya L. leaf extract against diabetes.
| Treatment | Results | References |
|---|---|---|
| The ethanolic aqueous extract of | (i) Reduced glucose levels in the blood at the end of the fifth day of treatment. | [ |
| The aqueous extract of | (i) Delay in attaining the maximum plasma concentrations of amiodarone, extract and amiodarone increased the drug bioavailability | [ |
| Aqueous extract of | (i) Significant reduction in blood glucose level and serum lipid profile levels due to antihyperglycemic and hypolipidemic properties. | [ |
| Ethanolic extract of | (i) Significant reduction in glucose level (123.50 mg/dL), total cholesterol, triglyceride (1.24 mg/dL), and serum urea (12.35 mg/dL). | [ |
| Ethanolic leaf extracts of | (i) Good effects on plasma insulin, cholesterol, triglyceride, and HDL cholesterol levels | [ |
| Aqueous extract of | (i) Significantly reduced glucose level from 275.00 to 85 mg/dL, total cholesterol from 117.70 to 98.50 mg/dL, total glycerides from 107.10 to 97.21 mg/dL, and LDL from 49.44 to 44.01 mg/dL | [ |
| The administration at a dose of 1000 mg/kg body weight of papaya leaf ethanol extract in diabetic Wistar mice. | Reduce blood glucose levels in diabetic Wistar mice | [ |
Figure 4Antidiabetic activities of Carica papaya extract (CPE).
Medicinal potential of Carica papaya L. leaf extract as neuroprotective, anti-inflammatory, and antibacterial herbal medicine.
| Treatment | Results | References |
|---|---|---|
| Ethanolic extract of | (i) Reduction in inflammation and in carrageenan-induced paw edema, granuloma (cotton pellet induced) in arthritic mice | [ |
| Aqueous | (i) Increment in protein content and also increased production of antibodies against ovalbumin | [ |
| Alcoholic | (i) Neuroprotective effect of | [ |
| Methanol and aqueous extracts of | Inhibits the growth of | [ |
AgNPs synthesis using C. Papaya leaf with well-defined applications, characterization techniques, particle characteristics, and operating conditions.
| Applications | Operating conditions | Characterization techniques used | Particle characteristics | Reference |
|---|---|---|---|---|
| (i) AgNPs exhibited inhibitory effect against both gram-positive and negative bacterial species | AgNO3 (1 mM); extract: AgNO3 (1 : 4), heated at 60°C for 5–10 min and incubated on sand bath for 30 min | UV-vis, FTIR, SEM-EDX, TEM, XRD | Size: 50-200 nm; shape: spherical | [ |
| (i) Antibacterial activity against human pathogens such as | AgNO3 (2 mM); kept at 37°C in dark condition for 72 h | HR-TEM, UV-vis, FTIR, XRD | Size: 6-18 nm shape: face-centered cubic crystalline (fcc) | [ |
| (i) NPs exhibited excellent antibacterial activity against | AgNO3 (1 mM); aqueous leaf extract: AgNO3 (1 : 9); maintained at 27°C/24 h | FTIR, AFM, XRD | Size: 7–32 nm shape: | [ |
| (i) Showed antibacterial activity against | AgNO3 solution | UV-vis, FESEM, FTIR, EDX | Size: 13-69 nm shape: spherical | [ |
| (i) Showed exhibited inhibitory against both gram-positive and negative bacterial species | AgNO3 (0.01 M); aqueous leaf extract: AgNO3 (1 : 4), heated on a sand bath at 70°C for 20 min | UV-vis, SEM | Size: 5 to 50 nm shape: spherical | [ |
| (ii) Antimicrobial activity against | 1% silver nitrate (AgNO3); maintained at 40°C temperature for 24 h. | UV-Vis | Size: 250 nm shape: ND | [ |
| (i) Antioxidant | AgNO3 (1 mM); extract: AgNO3 (1 : 9); mixture was boiled at 45°C for 30 min | HE-TEM, XRD, FE-SEM, EDX | Size: 10 nm shape: spherical | [ |
| (i) Blue CP and yellow 3RS dyes degradation | AgNO3 (0.002 M); incubated for 24 h at 37°C | TEM, EDS, UV-vis | Size: 10-70 nm | [ |
| (i) Antibacterial activity against human pathogens ( | AgNO3 (1 mM) | UV–vis, FTIR, XRD, SEM, TEM | Size: 16 nm to 18 nm shape: spherical | [ |
| (i) Better efficacy against cancer cells and was also relatively less toxic to normal cells | AgNO3 (1 mM); 200 | TEM, STM, SEM, EDS, XRD, FTIR | Size: 10 to 20 nm shape: spherical | [ |
| (i) Exhibited an excellent antibacterial activity against gram-positive and gram-negative pathogenic bacterial strains like ( | AgNO3 (1 mM); extract: AgNO3 (1 : 9); incubated for 24 h at 37°C | UV–vis, FTIR, SEM, EDX, DLS | Size: 80 nm shape: spherical | [ |
| (i) Possessed potential antibacterial activity against | AgNO3 (1 mM); kept at 37°C for 3 hours | UV-vis, TEM, FTIR | Size: 13-17 nm shape: spherical | [ |